$OGN News

Organon & Co. (OGN) Is a Trending Stock: Facts to Know Before Betting on It

Organon to Report Third Quarter 2026 Results in Its Regularly Scheduled Form 10-Q Filing

Organon Announces Positive Interim Phase 3 Study Results for MIUDELLA®, a Hormone-Free, Intrauterine Device (IUD), Through 6 Years of Use to Be Presented at the 2026 Society of Family Planning Annual Meeting

Organon To Present Data From Its Current Phase 3 Trial Of MIUDELLA Intrauterine Device At 2026 Society Of Family Planning Annual Meeting

Investors Heavily Search Organon & Co. (OGN): Here is What You Need to Know

Here is What to Know Beyond Why Organon & Co. (OGN) is a Trending Stock

Organon to Present New Real-World Analysis of VTAMA® (tapinarof) Cream, 1%, at the 2026 Fall Clinical Dermatology Conference

Organon Canada announces the Approval and Availability of NDUVRA® (tapinarof cream), 1%, a New Steroid-Free Topical Treatment for Moderate to Severe Atopic Dermatitis in Adult and Pediatric Patients 2 Years of Age and Older

Organon Canada Announces Availability Of NDUVRA To Treat Moderate To Severe Atopic Dermatitis

Why Organon (OGN) Is Getting Attention Today

Organon (OGN) Wins FDA Review Acceptance For Its Hormone Free Contraceptive Device

Is Trending Stock Organon & Co. (OGN) a Buy Now?

PhaseV Appoints Biopharma Leaders Klaus Beck and Avi Kulkarni to Scientific Advisory Board to Guide Expansion of AI Conductor

Organon Announces US FDA Has Accepted for Review a Supplemental New Drug Application for MIUDELLA®, a Hormone-Free Intrauterine Device

Organon: A Merger-Arbitrage Hold With Limited Upside

Organon & Co. (OGN) is Attracting Investor Attention: Here is What You Should Know

Organon Opens REMS Program for MIUDELLA® Ahead of Anticipated Commercial Availability

Compared to Estimates, Organon (OGN) Q2 Earnings: A Look at Key Metrics

Organon (OGN) Lags Q2 Earnings Estimates

Organon Announces Quarterly Dividend